Brazilian Government Approves Medical Marijuana, Inc.’s New Partnership HempMeds Brasil(TM) and Their Products as a Prescription Medication for Import
Historic Milestone: U.S. Company’s Cannabis Product Approved for Import in Brazil; the Brazilian Government Has Subsidized the Product for Many and HempMeds Brasil(TM) Has Received Its First Insurance ReimbursementsCannabis has been illegal in Brazil — regardless of whether the origin is from marijuana or hemp. That has all changed thanks to two mothers, one in the United States and one in Brazil — and Real Scientific Hemp Oil(TM) (RSHO(TM)), a Medical Marijuana, Inc.-marketed hemp product via its partnership with HempMeds Brasil(TM).
Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public thatHempMeds Brasil’s(TM) RSHO(TM) product has been written into world history as the first cannabis product to be approved for import by Brazil’s federal government and used as a prescription for approved medical indications within Brazil including epilepsy (CDKL5 and Dravet Syndrome). HempMeds Brasil(TM) is providing the RSHO(TM) exclusively for the Brazilian marketplace while under temporary broad approval for additional medical indications, subject to clinical trials within the country.
Today, any resident of Brazil who has a government-approved medical indication can have access to RSHO(TM) hemp oil products and may do so with both a doctor’s prescription and government-approved import documentation. ANVISA has issued a statement on the agency’s website, featuring a photo of a tube of RSHO(TM) from HempMeds Brasil(TM), and explains how to apply for an import certificate. Currently the product is approved via direct registration from an individual consumer, HempMeds Brasil(TM) has been working for over a year on its formal product drug application and submission. The company expects this to take through 2015 to complete.
“Brazil is a shining example of how a national government has responded to humanitarian interests and has swiftly and diligently passed favorable legislation on behalf of the health and well-being of its people — children in particular,” states Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “We are truly inspired by the swiftness and the capability of the Brazilian government to overcome politics in granting nationwide access to CBD hemp oil products. Their decisive action is a stellar example for the rest of the world — they rewrote history. The products have been approved for import for six medical indications, five of these indications are subject to future clinical trials – we will update shareholders on developments.”
Dr. Titus continues, “I would like to say thank you to our team of dedicated men and women across the world who have made history, for without you none of this would be possible. To the parents and families in the U.S. and Brazil who have fought to have access to these products in Brazil our hearts are with you and your children. Thank you for your trust and belief in our company and our natural botanical products.”
About HempMeds Brasil(TM)
About Medical Marijuana, Inc.
Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. HempMeds Brasil(TM) only sells its products to the Brazilian marketplace via prescription and proper approval of the Brazilian health authority ANVISA. None of these products are for sale in the United States of America or any other marketplace besides Brazil currently.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabinoids are a natural constituent of hemp oil.
For further information, please contact: Public Relations contact: Andrew Hard Corporate Spokesperson CMW Media P. 858-380-5478 andrew.hard@cmwmedia.com Corporate contact: Medical Marijuana, Inc. Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc Investor Relations: GH Investment Advisors 550 West "C" Street, Ste. 2040 San Diego, CA 92101 Nick Massalas Office: (858) 264-6500 Toll Free: (877) 964-6463 info@ghinvestmentadvisors.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
